featured
2024 Top Story in Oncology: Outcomes in Patients With Multiple Myeloma With CAR T-Cell Therapy in the Standard-of-Care Setting
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Sidana S, Patel KK, Peres LC, et al. Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma. Blood. 2024 Oct 4. Doi: 10.1182/blood.2024025945. Online ahead of print.
- Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324.
Disclosure statements are available on the authors' profiles: